Wellgistics Health Files S-1/A Amendment 6

TL;DR

Wellgistics Health (fka Danam Health) filed S-1/A #6 for IPO. Moving forward.

AI Summary

Wellgistics Health, Inc. (formerly Danam Health, Inc.) filed an S-1/A amendment on December 18, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Tampa, FL, and operates in the wholesale drug and sundries sector. This filing is Amendment No. 6 to its Form S-1 Registration Statement.

Why It Matters

This S-1/A filing indicates Wellgistics Health is moving forward with its IPO process, providing updated information to potential investors about its business and financial standing.

Risk Assessment

Risk Level: medium — As an S-1/A filing for an IPO, the company is seeking public investment, which inherently carries risks associated with new public offerings and the company's specific business sector.

Key Numbers

• 333-280945 — SEC File Number (Identifies the specific registration statement with the SEC.)
• Amendment No. 6 — Amendment Number (Indicates this is the sixth update to the original S-1 filing.)

Key Players & Entities

• Wellgistics Health, Inc. (company) — Registrant
• Danam Health, Inc. (company) — Former company name
• 20241218 (date) — Filing date
• 3000 Bayport Drive Suite 950 Tampa, FL 33607 (address) — Principal executive offices
• Timothy Canning (person) — Agent for service
• Kate L. Bechen (person) — Copies to counsel
• Robin K. Lehninger (person) — Copies to counsel
• Louis D. Kern (person) — Copies to counsel
• Dykema Gossett PLLC (company) — Counsel

FAQ

Key Financial Figures

• $4.50 — ice of our Common Stock will be between $4.50 per share and $5.50 per share. We belie
• $5.50 — ock will be between $4.50 per share and $5.50 per share. We believe that upon complet
• $0.0001 — o; refer to the common stock, par value $0.0001 per share, of Wellgistics Health, Inc.

Filing Documents

• forms-1a.htm (S-1/A) — 3263KB
• ex23-1.htm (EX-23.1) — 5KB
• logo_01.jpg (GRAPHIC) — 13KB
• formdrs_003.jpg (GRAPHIC) — 148KB
• formdrs_15.jpg (GRAPHIC) — 46KB
• formdrs_016.jpg (GRAPHIC) — 67KB
• formdrs_002.jpg (GRAPHIC) — 474KB
• 0001493152-24-050510.txt ( ) — 4299KB

Underwriting

Underwriting discount (1) $ 0.35 $ 315,000 Proceeds, before expenses, to us (2) $ 4.65 $ 4,185,000 (1) We have agreed to pay the representative a discount equal to 7% of the gross proceeds of the Offering. For a description of the other compensation to be received by the representative, see “ Underwriting ” beginning on page 101. (2) Excludes fees and expenses payable to the underwriters and other expenses of this Offering. The underwriters are offering the units on a firm commitment basis and expects to deliver the Common Stock to purchasers on or about [], 2024. Craft Capital Management LLC D. Boral Capital LLC The date of this prospectus is [], 2024 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 MARKET AND INDUSTRY DATA 1 FREQUENTLY USED TERMS 2 PROSPECTUS SUMMARY 5 THE OFFERING 9 RISK FACTORS 10 CAUTIONARY 41 USE OF PROCEEDS 42 DIVIDEND POLICY 43 CAPITALIZATION 44

DILUTION

DILUTION 45 SELECTED FINANCIAL DATA 46 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 47 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS HEALTH, INC. 51 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS LLC 56

BUSINESS

BUSINESS 63 MANAGEMENT 81 EXECUTIVE COMPENSATION 86 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 90 PRINCIPAL STOCKHOLDERS 92 DESCRIPTION OF CAPITAL STOCK 93 SHARES ELIGIBLE FOR FUTURE SALE 96 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 97

UNDERWRITING

UNDERWRITING 101 LEGAL MATTERS 105 EXPERTS 105 WHERE YOU CAN FIND MORE INFORMATION 105 INDEX TO FINANCIAL STATEMENTS F-1 DEALER PROSPECTIVE DELIVERY OBLIGATION Until [ ] (the 25th day after the date of this offering), all dealers that effect transactions in these securities, whether or not participating in this Offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwriters have not authorized anyone to provide you with information or to make any representations other than contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus, any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making an offer to sell our Common Stock in any jurisdiction where the offer or sale thereof is not permitted. You should not assume that the information appearing in this prospectus any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those da

View Full Filing

View this S-1/A filing on SEC EDGAR